News
BNGO
1.050
-2.78%
-0.030
Three Publications Demonstrate Bionano's OGM's Utility For Cell And Gene Therapy; Publications Include Niño Jesús University Children's Hospital; Ruhr-University Bochum And Janssen
Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development. OGM can be highly sensitive for genome-wide detection of on and off target effects that may limit the utility of stem cell lines and CAR-T cell products.
Benzinga · 18h ago
BIONANO ANNOUNCES THREE PUBLICATIONS DEMONSTRATING OGM’S UTILITY FOR CELL AND GENE THERAPY
Reuters · 18h ago
Weekly Report: what happened at BNGO last week (0513-0517)?
Weekly Report · 1d ago
Bionano Genomics Is Maintained at Buy by BTIG
Dow Jones · 5d ago
Bionano Genomics Price Target Cut to $2.00/Share From $3.00 by BTIG
Dow Jones · 5d ago
BTIG Maintains Buy on Bionano Genomics, Lowers Price Target to $2
Benzinga · 5d ago
Strong Performance and Strategic Initiatives Underpin Buy Rating for BioNano Genomics
TipRanks · 5d ago
Weekly Report: what happened at BNGO last week (0506-0510)?
Weekly Report · 05/13 10:50
Bionano stock climbs 7% in wake of Q1 report, software upgrades
Bionano Genomics stock climbs 7% in wake of Q1 report, software upgrades. The company has upgraded its computational tools for cancer analysis. Bionano also released a better-than-expected Q1 earnings report and reiterated its 2024 revenue guidance of $37M to $41M.
Seeking Alpha · 05/09 18:50
Bionano Genomics Inc reports results for the quarter ended in March - Earnings Summary
Bionano Genomics Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 51 cents per share. Revenue rose 18.3% to $8.77 million from a year ago. Shares of BionanoGenomics Inc have fallen by 17.1% this quarter.
Reuters · 05/09 18:26
BioNano Genomics (BNGO) Gets a Buy from Scotiabank
TipRanks · 05/09 11:25
Bionano Genomics, Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 05/09 09:47
BNGO Stock Earnings: Bionano Genomics Beats EPS, Beats Revenue for Q1 2024
Bionano Genomics reported earnings per share of -60 cents for the first quarter of 2024. The company reported revenue of $8.77 million. This was 3.29% better than the analyst estimate for revenue. BionanoGenomics is a company that develops DNA sequencing technology.
Investorplace · 05/09 00:58
Bionano Genomics up 7% on narrowed quarterly loss, revenue beat
Bionano Genomics up 7% on narrowed quarterly loss, revenue beat. The company reported Q1 2024 results that showed its quarterly loss narrowed year over year. Bionano also posted a revenue beat in the quarter. The stock is up 7 percent in after-hours trading.
Seeking Alpha · 05/08 20:54
BIONANO GENOMICS INC: EXPECTS REDUCTION WILL BE SUBSTANTIALLY COMPLETED BY JUNE 30
Reuters · 05/08 20:29
BIONANO GENOMICS INC: ON MARCH 5, CO FILED REPORT DISCLOSING CORPORATE REORGANIZATION PLAN
Reuters · 05/08 20:29
*Bionano Genomics Sees 2Q Rev $7.8M-$8.2M >BNGO
Dow Jones · 05/08 20:09
*Bionano Genomics 1Q Rev $8.8M >BNGO
Dow Jones · 05/08 20:09
Bionano Genomics reports Q1 results
Seeking Alpha · 05/08 20:05
More
Webull provides a variety of real-time BNGO stock news. You can receive the latest news about Bionano Genomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About BNGO
Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).